Market Newsdesk

AKRON, Ohio, March 31, 2021 /PRNewswire/ — The Goodyear Tire & Rubber Company (NASDAQ: GT) today announced that it has commenced a public offering of $1 billion aggregate principal amount of 10- and 12-year senior notes. The notes will be senior unsecured obligations of the company. Issuance and sale of the notes is subject to market and other customary closing conditions.

Goodyear intends to use the net proceeds from this offering, together with its current cash and cash equivalents, to redeem in full its outstanding $1 billion 5.125% senior notes due 2023 following, and subject to, the completion of this offering, at a redemption price equal to par plus accrued and unpaid interest to the redemption date.

Citigroup Global Markets Inc.; Barclays Capital Inc.; BNP Paribas Securities Corp.; BofA Securities, Inc.; Credit Agricole Securities (USA) Inc.; Deutsche Bank Securities Inc.; Fifth Third Securities, Inc.; Goldman Sachs & Co. LLC; J.P. Morgan Securities LLC; MUFG Securities Americas Inc.; PNC Capital Markets LLC; SMBC Nikko Securities America, Inc. and Wells Fargo Securities, LLC are acting as the joint-bookrunning managers for the offering.  BBVA Securities Inc.; BMO Capital Markets Corp.; Capital One Securities, Inc.; Citizens Capital Markets, Inc.; Huntington Securities, Inc.; KeyBanc Capital Markets Inc. and Regions Securities LLC are acting as co-managers for the offering.

The offering will be made under an effective shelf registration statement that was filed with the U.S. Securities and Exchange Commission on May 13, 2020. The offering of the notes may be made only by means of a prospectus supplement and accompanying prospectus, copies of which may be obtained from:

This news release shall not constitute a notice of redemption under the optional redemption provisions of the indenture governing the 5.125% senior notes due 2023. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Goodyear is one of the world’s largest tire companies. It employs about 62,000 people and manufactures its products in 46 facilities in 21 countries around the world. Its two Innovation Centers in Akron, Ohio, and Colmar-Berg, Luxembourg, strive to develop state-of-the-art products and services that set the technology and performance standard for the industry.

Certain information contained in this press release constitutes forward-looking statements for purposes of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995. There are a variety of factors, many of which are beyond our control, that affect our operations, performance, business strategy and results and could cause our actual results and experience to differ materially from the assumptions, expectations and objectives expressed in any forward-looking statements. These factors include, but are not limited to: the impact on us of the COVID-19 pandemic; our success in completing our pending acquisition of Cooper Tire & Rubber Company, and our ability to achieve the expected benefits of such acquisition; our ability to implement successfully our strategic initiatives; actions and initiatives taken by both current and potential competitors; deteriorating economic conditions or an inability to access capital markets; increases in the prices paid for raw materials and energy; a labor strike, work stoppage or other similar event; foreign currency translation and transaction risks; work stoppages, financial difficulties or supply disruptions at our suppliers or customers; the adequacy of our capital expenditures; our failure to comply with a material covenant in our debt obligations; potential adverse consequences of litigation involving the company; as well as the effects of more general factors such as changes in general market, economic or political conditions or in legislation, regulation or public policy. Additional factors are discussed in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

View original content to download multimedia:http://www.prnewswire.com/news-releases/goodyear-announces-offering-of-senior-notes-301259514.html

SOURCE The Goodyear Tire & Rubber Company

Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 2028¹

VANCOUVER, BC, March 31, 2021 /PRNewswire/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) an industry leader in advanced proprietary technology for psychedelic therapy, that also identifies, develops, and commercializes various proprietary  products that enhance mental health and wellness, ease suffering, and increase productivity, is pleased to announce that it has submitted a provisional patent application with the United States Patent and Trademark Office to cover iSTRYM, the company’s proprietary digital therapeutics (DTx) tool.

iSTRYM is an investigating technology that focuses on patient feedback and data-driven insights into the efficacy of treatments in order to assist in the application of more effective and more efficient diagnosis techniques and treatments. It’s a technology that is targeted for both therapists and patients.

MINDCURE is investing significant resources into its near term revenue strategy, developing the proprietary iSTRYM technology and digital therapeutics (DTx), targeting the value that these tools offer to the emerging markets of psychedelics and psychedelic-assisted therapy. DTx are evidence-based therapies delivered via software to complement existing treatments. What is unique about DTx compared to other health care technologies is that they require approval from regulatory bodies, unlocking the potential for insurer paid revenue streams. One approved by regulatory bodies, our technology and the fact based developed & more efficient therapies it gives birth to, will be adopted and utilized across a majority of practitioner therapists and patients, and become the service tool of choice. Its designed to be the model platform that becomes the industry backbone to identify and aggregate the best and most efficient protocols optimized by AI. It quantifies a number of therapies to create a universe of personalized and precision medical therapies identified in trials and individually recommended for each patient’s unique situation and needs.

iSTRYM will arm therapists with better tools and patient insights rooted in data while providing quantified care at scale to individuals who go through the therapeutic process. 

“When people think of MINDCURE, I want them to see us as the leader in technology and specifically digital therapeutics for the psychedelics industry,” said Kelsey Ramsden, President and CEO, MINDCURE. “We intend to build iSTRYM into the world’s largest data repository of psychedelic experiences, backed by science and built on trust. This is why we were so thrilled to recently receive ethics approval from Veritas for our integration protocol research study, and why we view this provisional patent application as the next milestone for iSTRYM.” She continued: “Digital therapeutics (DTx) were gaining popularity as tools to help slash the $3 trillion annual spending (in the US alone) on chronic disease, and the pandemic has vaulted digital therapies into that spotlight. We are at the right place in time and  we believe that could bode well for our shareholders.”

Pre-pandemic, the global DTx industry was projected to reach $13.8 billion in 2025 at a tremendous CAGR of 20.5 percent, but the increased acceptance and reliance on digital health care brought about by COVID-19 has increased this projection significantly, as new forecasts anticipate the DTx market to be a $56 billion global opportunity by 2025.²

“We believe that iSTRYM has the potential to revolutionize the way mental health is treated across the world, and know the importance of patent protection as we invest significant resources in its development and commercialization,” said Geoff Belair, CTO, MINDCURE.

The patent application was submitted on March 22, 2021 as App. No. 63/167,611.

ABOUT iSTRYM

iSTRYM

, a First-of-Its-Kind, AI-Driven Mental Wellness Optimization Tool. This  proprietary technology connects researchers, therapists, and individuals to achieve tangible results in mental health care. iSTRYM enables users to collect data, monitor progress, and connect to a network of support where the data can be the source of new procedures for practitioners and patients alike. iSTRYM enables psychedelic researchers to deliver results faster with cleaner data and deeper, richer insights. It also allows a built in distribution network to share commercialized proprietary protocols. iSTRYM also arms therapists with the most robust repository of science–backed treatment protocols and care practice packages ever compiled. Therapists can provide personalized care with deeper insights and long-tail support, while increasing clinic revenue, reducing clinic hours, and increasing positive patient outcomes. We believe that this will make therapies in general and customized individual therapies effectively evolve with more experience using our science–backed content with therapists and individuals around the world.  For more information go to: https://mindcure.com/tech/ 

The Company also announces it has granted a total of 400,000 stock options to certain employees or consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.60 per share and subject to the terms of the Plan.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: iSTRYM being the lynchpin for MINDCURE’s near-term revenue strategy; MINDCURE receiving a patent for iSTRYM; iSTRYM arming therapists with better tools and patient insights rooted in data while providing quantified care at scale to individuals who go through the therapeutic process; iSTRYM potentially becoming the world’s largest data repository of psychedelic experience; and iSTRYM revolutionizing the way mental health is treated across the world.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; iSTRYM will receive its full patent from the United States Patent and Trademark Office; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments iSTRYM may not receive its full patent from the United States Patent and Trademark Office; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

View original content to download multimedia:http://www.prnewswire.com/news-releases/mindcure-files-provisional-patent-application-for-istrym-its-proprietary-ai-digital-therapeutics-dtx-saas-platform-designed-to-enhance-effectiveness-of-psychedelic-assisted-therapies-for-practitioners-and-patients-301259470.html

SOURCE Mind Cure Health Inc.

High-Grade Silver and Gold Intersections Confirmed in Step-Out Holes


Significant Follow-Up Drill Program to Commence Shortly

VANCOUVER, BC, March 31, 2021 /PRNewswire/ – Summa Silver Corp. (“Summa” or the “Company”) (TSXV: SSVR) (OTCQB: SSVRF) (Frankfurt:48X) is pleased to announce additional high-grade silver-gold intersections from the Hughes Property in central Nevada.  These results build on previously reported intercepts and demonstrate high-grade continuity along numerous high-priority veins. Results from this batch of assays are from three vein sets in the Belmont Mine target.

Key Highlights

Rescue Veins in the Belmont Mine Target Area:

• 2,995 g/t silver equivalent (1,480 g/t Ag and 15.15 g/t Au) over 0.8 m from 378.5 m in SUM20-19
• SUM20-19 is a 50 m step-out from SUM20-06 which intersected 3,760 g/t AgEq (1,762 g/t Ag and 19.99 g/t Au) over 2.5 mand a 50 m step-out from SUM20-20 which intersected 6,220 g/t AgEq (2,910 g/t Ag and 33.1 g/t Au) over 0.7 m (see attached figures).

725 and IOU Veins in the Belmont Mine Target Area:

• 1,269 g/t silver equivalent (580 g/t Ag and 6.89 g/t Au) over 0.7 m from 156.0 m in SUM20-28 (450 m northwest of the Rescue vein series)
• 823 g/t silver equivalent (393 g/t Ag and 4.3 g/t Au) over 0.6 m from 395.8 m in SUM20-23 (250 m north of the Rescue vein series)

Note: AgEq based on 100 (Ag):1 (Au), True widths are unknown.

Further Assays Pending and Drilling Imminent:  Assays remain pending for 9 holes from the 2020 drill program with the 2021 drill program set to begin in the first half of April.  

Exploration Underway: The Company is currently conducting a pre-drilling exploration program which includes an airborne LiDAR survey and geological mapping. Soil and induced polarization surveys focused on the eastern extension of the Tonopah District are also scheduled for this spring.

Fully Funded for Aggressive Drill Programs: The Company is well funded with approximately $13.2M in working capital.  

Galen McNamara, CEO, stated: “Multiple vein systems in the historic Belmont Mine continue to return exceptional grades with continuity now shaping up nicely. With this year’s exploration now beginning, our focus will be on both mineral resource style step-outs, and discovery of additional strong mineralization on the eastern extension of what is one of the most heavily endowed silver districts in the United States.”

Table 1: Assay Results – Belmont Mine Target Area

Phase I Program Summary

The Phase I drill program in 2020 was designed to test the lateral and vertical extents of structurally controlled, epithermal-related, high-grade silver and gold mineralization historically mined in the Tonopah District. Nineteen holes tested numerous steeply-dipping, west-southwest striking veins and secondary splays in the Belmont Mine target area. At each vein location (e.g., Rescue, IOU and 725), a series of holes tested the along-strike and down-dip extensions of mineralization in approximately 50 m centered piece-points along the vein (see attached figures). In most cases, mineralization consists of locally Ag-sulfasalt bearing, banded to brecciated quartz ± adularia veins with associated argillic alteration halos hosted in intermediate to felsic volcanic and volcaniclastic rocks. Vein thickness varied from a few centimeters to a few meters. Assays for 5 holes are reported in Table 1 and results are still pending from 9 holes.

Phase II Program

A significant follow-up drill program is planned and will commence shortly. A drill contractor has been selected and program details will be released once targets are ranked and prioritized.

Remote Sensing and Geological Mapping

The company is currently flying a LiDAR (light detection and ranging) survey and are collecting high-resolution ortho-images over the entire project area. The data will be used to identify areas of historic disturbance potentially related to surface mineralization and to provide robust topographic control for future modelling and ground-based surveys. The company has also initiated a property-scale geological mapping program aimed at refining the geological model for the district. A focus will be on defining the footprint-extent of outcropping hydrothermally altered bedrock as well as mapping along key structures. Systematic rock-chip samples will be collected to aid in advancing the geochemical model for the district as well as defining new drill targets.

Table 2: Drillhole Information

Analytical and QA/QC Procedures

All samples were sent to ALS Global Ltd. (“ALS”) in Reno, NV for preparation and then to North Vancouver, Canada for analysis. ALS meets all requirements of International Standards ISO/IEC 17025:2005 and ISO 9001:2015 for analytical procedures. Samples were analyzed for gold via fire assay with an AA finish (“AU-AA23”), and 48 other elements, including silver, via a combination of atomic emission spectroscopy and mass spectroscopy after four-acid digestion (“ME-MS61”). Samples that assayed over 10 ppm Au via AU-AA23 were re-run via fire assay for Au with a gravimetric finish (“AU-GRA21”). Samples that assayed over 100ppm Ag via ME-MS61 were re-run via fire assay for Ag with a gravimetric finish (“AG-GRA21”). In addition to ALS quality assurance / quality control (“QA/QC”) protocols, Summa Silver implements an internal QA/QC program that includes the insertion of sample blanks, duplicates and certified reference materials at systematic and random points in the sample stream.

Qualified Person

The technical content of this news release has been reviewed and approved by Galen McNamara, P. Geo., the CEO of the Company and a qualified person as defined by National Instrument 43-101.

About Summa Silver Corp

Summa Silver Corp is a Canadian junior mineral exploration company. The Company has options to earn 100% interests in the Hughes property located in central Nevada and the Mogollon property located in southwestern New Mexico. The Hughes property is host to the high-grade past-producing Belmont Mine, one of the most prolific silver producers in the United States between 1903 and 1929. The mine has remained inactive since commercial production ceased in 1929 due to heavily depressed metal prices and little to no modern exploration work has ever been completed.

Follow Summa Silver on Twitter: @summasilver

LinkedIn:
https://www.linkedin.com/company/summa-silver-corp/

ON BEHALF OF THE BOARD OF DIRECTORS


“Galen McNamara”


Galen McNamara, Chief Executive Officer
[email protected] 
www.summasilver.com

Investor Relations Contact:
Kin Communications
Nima Shafigh
604-684-6730
[email protected]

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary note regarding forward-looking statements

This news release contains certain “forward looking statements” and certain “forward-looking information” as defined under applicable Canadian and U.S. securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as “may”, “will”, “should”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “continue”, “plans” or similar terminology. The forward-looking information contained herein is provided for the purpose of assisting readers in understanding management’s current expectations and plans relating to the future. These forward–looking statements or information relate to, among other things: the release of assays, and the exploration and development of the Company’s mineral exploration projects.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual actions, events or results to be materially different from those expressed or implied by such forward-looking information, including but not limited to: the requirement for regulatory approvals; enhanced uncertainty in global financial markets as a result of the current COVID-19 pandemic; unquantifiable risks related to government actions and interventions; stock market volatility; regulatory restrictions; and other related risks and uncertainties.

Forward-looking information are based on management of the parties’ reasonable assumptions, estimates, expectations, analyses and opinions, which are based on such management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect.

The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

View original content to download multimedia:http://www.prnewswire.com/news-releases/summa-silver-drills-2-995-gt-silver-equivalent-over-0-8-m-at-the-hughes-property-nevada-301259117.html

SOURCE Summa Silver Corp.

ROCHESTER, N.Y. and GRONINGEN, Netherlands, March 31, 2021 /PRNewswire/ — Hyzon Motors Inc. (“Hyzon” or “the Company”), a leading global supplier of zero-emission hydrogen fuel cell-powered commercial vehicles, today announced it has launched leasing service for the provision of heavy-duty fuel cell electric vehicles (FCEVs) to its customers in the European Union.

As announced on February 9, 2021, Hyzon has entered into a definitive agreement for a business combination with Decarbonization Plus Acquisition Corporation (NASDAQ: DCRB, DCRBW, DCRBU), a publicly-traded special purpose acquisition company (SPAC) that would result in Hyzon becoming a publicly listed company. Completion of the proposed transaction is subject to customary closing conditions, and is expected to occur in the second quarter of 2021.

Through the leasing service, Hyzon intends to enable potential European Union customers to operate the Company‘s branded vehicles through a leasing model, and to thereby fast-track the transition of their fleets to hydrogen fuel, without compromising on performance.

Hyzon and its partners have been actively developing complete end-to-end lifecycle solutions that enable fleet operators to viably make the transition to hydrogen fuel cell commercial vehicles. The Company’s new lease offering represents the first step in the development of a holistic fleet leasing offering for the European market that is expected to include hydrogen fuel, insurance, service and maintenance for Hyzon and Hyzon-branded vehicles.

Hyzon Sets Ambition to Achieve TCO Parity in Europe

The Company also announced today that it aims to be among the first companies to supply customers with a hydrogen fuel cell truck at total cost of ownership (TCO) parity with diesel-powered commercial vehicles in Europe. With its leading fuel cell technology, and incentives available in Europe, Hyzon expects to help customers achieve TCO parity through its alliance with multiple hydrogen infrastructure partners.

Given the momentum behind hydrogen across Europe, this region is anticipated to lead the roll-out of hydrogen mobility worldwide. As a hydrogen heavy mobility category leader, Hyzon expects to play a significant role in the European Union’s transition to hydrogen energy, through its manufacturing base in Groningen, The Netherlands. 

Craig Knight, Hyzon’s Chief Executive Officer, said, “We are excited to be able to offer this leasing service to our customers in Europe, and to support fleet operators in making the switch to hydrogen. This leasing service aims to offer the quickest possible pathway for our customers to make the transition to zero-emission hydrogen fuel cell-powered heavy vehicles that can go toe-to-toe with diesel engines on both costs and refueling time.“

For customer enquiries on leasing in the EU, please contact Hyzon Motors European Sales Manager André Lagendijk at [email protected]. 

About Hyzon Motors Inc.
Headquartered in Rochester, NY and with operations in Europe, Singapore, Australia and China, Hyzon is a leader in hydrogen mobility. Hyzon is led by co-founders George Gu, Craig Knight and Gary Robb and is a pure-play hydrogen mobility company with an exclusive focus on hydrogen in the commercial vehicle market. Utilizing its proven and proprietary hydrogen fuel cell technology, Hyzon aims to produce zero-emission commercial vehicles for customers in North America, Europe, and across the world. The company is contributing to the escalating adoption of hydrogen vehicles through its demonstrated technology advantage, leading fuel cell performance and history of rapid innovation. Visit www.hyzonmotors.com.  

Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act. All statements, other than statements of present or historical fact included in this press release, including those regarding Decarbonization Plus Acquisition Corporation’s (“DCRB”) proposed acquisition of the Company and DCRB’s ability to consummate the transaction, are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. Except as otherwise required by applicable law, DCRB and the Company disclaim any duty to update any forward looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release. DCRB and the Company caution you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of either DCRB or the Company, including risks and uncertainties described in the “Risk Factors” section of DCRB’s Preliminary Proxy Statement on Schedule 14A filed with the SEC on March 17, 2021 and other documents filed by DCRB from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Hyzon gives no assurance that Hyzon will achieve its expectations.

Hyzon Motors Contacts

For US, Europe and Global Media:
Brian Brooks
H+K Strategies
713.752.1901
[email protected]

For Australasian Media:
Fraser Beattie
Cannings Purple
+61 421 505 557
[email protected]

For Investors:
Caldwell Bailey
ICR, Inc.
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/hyzon-motors-launches-leasing-service-for-hydrogen-commercial-vehicles-in-europe-and-announces-ambition-to-be-among-first-to-achieve-tco-parity-in-europe-301259178.html

SOURCE HYZON Motors

JUPITER, Fla., March 31, 2021 /PRNewswire/ — Marizyme, Inc. (OTCQB: MRZM), a publicly traded global biotechnology company developing products to reduce the burden of ischemia-reperfusion injury in tissue grafting, and other surgical indications, announces that Board Chairman James Sapirstein has issued a Letter to Shareholders providing a business update for the Company’s recent activities. The full text of the Letter, which has also been posted to the Company’s website, is as follows:

Dear Fellow Shareholders:

This is our first shareholder letter in a while and our Board of Directors and I desired to communicate numerous corporate updates. First and foremost, Neil Campbell has resigned as CEO for good reason, and I have stepped in as interim CEO until we recruit a suitable replacement.  We have begun our search.  However, this has not slowed us down as we continue embarking on new sales opportunities for DuraGraft^® in several European countries as well as moving forward with our plans to seek clearance for DuraGraft in the United States.

Currently, DuraGraft has been authorized in 33 countries worldwide on four continents, and we have eight distributors covering eight countries, and we are adding more distributors each month with several in the final stages of due diligence before signing agreements.

We are working with our current distributor network to increase sales of DuraGraft in our current countries in the EU, South America, Turkey, Chile, and the Southeast Pacific region. The plan is to capitalize on the massive data from our EU Registry study of nearly 3,000 patients to show outcomes and the value of DuraGraft in select patient populations. This includes patients who have diabetes undergoing bypass surgery and those patients whose surgeon uses Endoscopic Vein Graph Harvesting (EVH) approach to support the utilization of first-in-class DuraGraft over other standard of care solutions.

Additionally, we have several partnership discussions that are nearing an agreement to increase our commercial footprint in the three Benelux countries, 18 Central and Eastern European countries, Mexico, Australia/New Zealand, UK, Ireland, France, South Korea, and a new distributor in Italy. We are also exploring strategic partnerships with companies who have interest in carrying DuraGraft as part of their portfolios to provide better outcomes with their complementary products and explore new applications with DuraGraft.     

Marizyme is currently pursuing discussions with the United States Food and Drug Administration (FDA) regarding United States regulatory strategy. Marizyme will pursue a marketing application for United States commercialization and is working towards FDA clearance in the third quarter of 2022.

Other recent significant highlights include:

• We announced a new distribution and channel partnership in Chile, with additional sales opportunities in other South American countries.
• We entered into a supply and distribution agreement with Abdera Financial, Inc., a Chilean-based distributor, to distribute DuraGraft in Chile, with potential expansion into other countries and regions of the South American market.
• We strengthened our Executive Team and Board of Directors:
• Steven Brooks, M.D., MBA, FACC – EVP of Medical and Regulatory Affairs, Chief Medical Office
• Donald Very, Ph.D. – EVP, Research & Development
• Roger Schaller – EVP, Commercial Operation
• Amy Chandler – EVP, Regulatory Affairs and Quality Management System
• William Hearl, Ph.D. – Independent Member of Board of Directors
• Julie Kampf – Veteran Business Executive, Independent Member of Board of Directors

With all the above in place, we continue to strive towards our goal of uplisting to NASDAQ in 2021.  This achievement would put Marizyme on a much larger stage, which should assist in facilitating many objectives.  Please visit www.marizyme.com, and view our team and each member’s credentials.

We are currently working on the Form 10-K for 2020, which should be filed shortly.  Inside the filing will be a more detailed discussion of our future plans.

Thank you again for your support as a MRZM shareholder.  We look forward to moving the Company towards its goals.

Sincerely,
James Sapirstein
Board Chairman

About Marizyme, Inc.
Marizyme is an integrated life sciences company dedicated to the acquisition, development and commercialization of therapies that minimize mortality and costs in the acute care space. The Company’s flagship product, DuraGraft^®, is an intra-operative vascular graft storage solution that inhibits endothelial damage and leads to improved clinical outcomes by reducing the incidence of complications associated with vein graft failure in bypass surgery. DuraGraft enhances coronary artery bypass grafting (CABG) surgical outcomes by significantly reducing major adverse cardiac events such as repeat revascularization and myocardial infarction. DuraGraft is approved for use in the EU and several Asian countries but is not yet approved for use in the U.S. Marizyme is also focused on the development and marketing of products based on its clinically tested and previously patented protease based therapeutic Krillase^® platform. Krillase is not approved for use in the U.S. For more information about Marizyme, visit www.marizyme.com.

Forward-Looking Statements
This press release may contain certain forward-looking statements, including those relating to Marizyme’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. The Company has made every reasonable effort to ensure the information and assumptions on which these statements are based are current, reasonable, and complete. However, a variety of factors, many of which are beyond the Company’s control, affect the Company’s operations, performance, business strategy and results and there can be no assurances that the Company’s actual results will not differ materially from those indicated herein. Additional written and oral forward-looking statements may be made by the Company from time to time. Forward-looking statements may be identified using forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, including those risks set forth in the Company’s risk factor disclosure in the reports that Marizyme files with the Securities and Exchange Commission (SEC File No. 000-53223), uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

CONTACT
Tiberend Strategic Advisors, Inc.
Investor
Miriam Weber Miller
212-375-2694
[email protected]

Media
Ingrid Mezo
646-604-5150
[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/marizyme-inc-issues-letter-to-shareholders-301259348.html

SOURCE Marizyme, Inc.

TORONTO, March 31, 2021 /CNW/ – Sleep Country Canada Holdings Inc. (“Sleep Country” or the “Company”) (TSX: ZZZ) is thrilled to announce that, further to its acquisition of Endy in November 2018, it has completed the acquisition with performance pay of $25 million in March 2021. The payment is testimony to Endy’s strong outperformance of all set growth and profitability targets in 2020. Since exploding onto the eCommerce scene in 2015, Endy has achieved over $250 million in revenue and has grown to become Canada’s leading online mattress brand and one of the country’s fastest-ever growing retail brands.

In November 2018, Sleep Country made its single most valuable investment to date through the acquisition of Endy for $88.7 million, paying $63.7 million in cash at closing and agreeing to pay up to $25 million in Q1 2021 based on Endy’s achievement of ambitious growth and profitability targets. With Endy surpassing every set metric, the acquisition has proven to be a spectacular success, driving tremendous value for customers, employees and shareholders in its first two years as part of the Sleep Country family.

“I am incredibly proud of a landmark year for Endy in 2020,” said Rajen Ruparell, Co-Founder, Endy. “What we have achieved is a testament to our brilliant team and our relentless focus on customer experience. We believe we are still in the early stages of building a truly iconic Canadian brand.”

The Endy acquisition is a successful milestone in the execution of Sleep Country’s strategic plan. Over the last several years, Sleep Country has been strategically investing and innovating in order to anticipate, adapt and evolve with the customer of today and tomorrow. The acquisition of Endy has significantly enhanced Sleep Country Canada Holdings Inc. competitive positioning by adding unmatched eCommerce infrastructure and digital acquisition capabilities through the Endy platform, substantially expanding its customer base and adding a suite of innovative, Canadian-made products to complement Sleep Country’s industry-leading assortment. Combined, the Sleep Country, Dormez-vous and Endy brands are unparalleled in the sleep retail landscape and are defining the way Canadians will choose to shop for sleep solutions for years to come.

Endy continues to operate separately from Sleep Country, encouraging the same competitive spirit that positions both companies as leaders in their respective spaces.

“We are incredibly excited about what the future holds for our partnership,” said Stewart Schaefer, Chief Business Development Officer, Sleep Country Canada. “We have barely scratched the surface on all that we plan to unleash between Endy and Sleep Country and have truly enjoyed working with their brilliant team. Each of our brands brings a best-in-class model of service to our combined customers. Our brands complement one another in offering a superior experience to a broader customer segmentation. Looking forward, our exceptional 2020 results serve as powerful momentum as we continue to build our sleep ecosystem and expand our leadership position in Canadian retail.”

Endy, founded in 2015 by Rajen Ruparell and Mike Gettis, continues to lead as an innovator in the eCommerce space. Since the acquisition, Endy has launched numerous new products including a duvet, weighted blanket and bed frame, while continuing to differentiate itself with its signature product, the Canadian-made Endy Mattress. Recently named Product of the Year Canada 2020 for Mattress-in-a-Box and Most Trusted Mattress-in-a-Box Brand 2021 by BrandSpark, Endy has become one of the country’s most widely owned and loved mattresses in a highly competitive market, with more than 250,000 sold and an average 4.9/5-star rating based on 20,000 customer reviews. The brand exclusively operates in Canada with its eCommerce website, endy.com, as its primary point-of-sale.

Additional notable achievements for Endy in 2020 include:

• Voted Product of the Year 2020 for Mattress-in-a-Box and Parent Tested, Parent Approved™
• Exceeded Canadians’ expectations of free and fast delivery, arriving on customers’ doorsteps in 3.2 days from order date, on average, nationwide
• Earned recognition as one of Canada’sGreat Places To Work for the second year running
• Reached a milestone of 10,000 mattresses donated to-date to Canadian charities as part of The Endy Donation Project
• Continued to drive innovation with Endy’s in-house marketing and creative teams, reaching 21.6 million Canadians through digital ads alone

In Spring 2020, Endy launched its Healthcare Heroes initiative, transforming on-call rooms at Canadian hospitals hard-hit by COVID-19 with new mattresses and bedding. These donations help ensure Canada’s frontline doctors and nurses can rest comfortably between patients and on multi-day shifts. Endy has expanded this initiative in 2021, with 16 Canadian hospitals supported to-date.

“The Endy team is best-in-class in Canada, and we applaud their record-breaking growth and commitment to innovation in eCommerce,” said David Friesema, CEO, Sleep Country Canada. “They have performed exceptionally well as part of the Sleep Country family and continue to set themselves apart as a leader in the digital space.”

Endy announced Alexandra Voyevodina-Wang as its new GM & President in November 2020. Previously, Alexandra served as Endy’s first-ever CFO, joining the team in 2016 as a key member of the brand’s early-stage growth team. In her new role, Alexandra oversees Endy’s growth strategy and day-to-day operations and looks forward to solidifying Endy’s reputation as a beloved Canadian brand with a customer-first focus. Rajen Ruparell remains active as founder and advisor to the company.

About Sleep Country

Sleep Country is Canada’s leading omnichannel specialty sleep retailer, with a national brick-and-mortar footprint and robust eCommerce platforms dedicated to supporting the health and wellbeing of Canadians by matching each customer to their best night’s sleep. Sleep Country operates under three retail banners (the “Banners”): “Sleep Country Canada”, with omnichannel operations in Canada excluding Québec; “Dormez-vous” with omnichannel operations in Québec and “Endy”, Canada’s leading online mattress-in-a-box retailer. As of March 16, 2021, Sleep Country has 283 stores and 17 distribution centres across Canada. All of the Company’s stores are corporate-owned, enabling it to develop and maintain a strong culture of customer service, resulting in a consistent and superior in-store and home delivery experience. Sleep Country also works closely with Canadian charities to donate new and gently used mattresses to families and children in need. 

For more information about the company visit www.sleepcountry.ca.

About Endy

Launched in 2015 and headquartered in Toronto, Endy (endy.com) is revolutionizing the way people sleep, through their ridiculously comfortable, supportive and Canadian-made mattress. Endy stands apart as one of Canada’s fastest-growing e-Commerce companies, and its fan-favourite, Canadian-made mattress was recently named Product of the Year Canada 2020 (Mattress-in-a-Box). The brand has expanded its assortment to include The Endy Pillow, The Endy Sheets, The Endy Mattress Protector, The Endy Duvet, The Endy Bed Frame, and The Endy Weighted Blanket. The proudly Canadian company works closely with Canadian charities to donate new and gently used mattresses to families and individuals in need. Endy is a wholly owned subsidiary of Sleep Country Canada Holdings Inc. (TSX:ZZZ).

SOURCE Sleep Country Canada Holdings Inc. Investor Relations

CINCINNATI, March 31, 2021 /PRNewswire/ — The Kroger Co. (NYSE: KR) will host a virtual 2021 Investor Day today to provide an update on the company’s strategic initiatives and plans to deliver strong and sustainable total shareholder return of 8% – 11%.

“Kroger continues to deliver for customers through our seamless ecosystem and relentless focus on freshness, value and convenience,” said Rodney McMullen, Kroger’s chairman and CEO. “Building upon the foundation established by our Restock Kroger transformation, and leveraging key learnings from operating during the pandemic, our strategy of Leading With Fresh and Accelerating With Digital is designed to convert our industry’s near-term tailwinds into long-term competitive advantages.

“Today, Kroger is uniquely positioned because of the strength of our assets and our competitive moats cultivated over several years of disciplined investment and focused execution. Our go-forward strategy builds on these strengths to drive share growth, increase profitability across digital, and deliver strong and sustainable total shareholder returns. Our talented and energized team is already delivering on our objectives, and we look forward to continuing to position Kroger to win in a post-COVID world.”

At today’s Investor Day event, Kroger’s leadership team will discuss the three core elements of its strategy:

• Grow sales and share by leading with fresh food;
• Increase profitability by accelerating with digital, which is now a growth engine; and
• Widen and deepen the competitive moats that will generate customer loyalty and market share gains – Seamless, Personalization, Fresh, and Our Brands.

Kroger’s leadership team will outline key growth opportunities that will drive the financial model forward including a clear path to deliver total shareholder return between 8% – 11%, through net earnings growth of 3% – 5% and strong and growing free cash flow to invest in growth initiatives and return cash to shareholders.

“Kroger is delivering on its value creation model, and over the period of 2019 to 2021, we expect to significantly exceed our total shareholder return target,” said Gary Millerchip, Kroger’s CFO. “The strength of our execution, combined with our strategic plans to continue to lead in fresh, accelerate digital, and grow alternative profit streams will enable us to achieve our 2021 guidance and deliver profitable growth beyond 2021.” 

Reconfirmed Full Year 2021 Guidance

* Without adjusted items, if applicable; Identical sales is without fuel; Operating profit represents FIFO Operating Profit. Kroger is unable to provide a full reconciliation of the GAAP and non-GAAP measures used in 2021 guidance without unreasonable effort because it is not possible to predict certain of our adjustment items with a reasonable degree of certainty. This information is dependent upon future events and may be outside of our control and its unavailability could have a significant impact on 2021 GAAP financial results.
** This rate reflects typical tax adjustments and does not reflect changes to the rate from the completion of income tax audit examinations, which cannot be predicted.
*** Identical sales, without fuel, guidance for 2-year basis represents the sum of actual 2020 identical sales and 2021 guidance. The 2-year basis guidance items denoted with CAGR represent the compounded annual growth rate utilizing 2019 as the base year.  Average free cash flow is the average of actual 2020 free cash flow and 2021 guidance.
**** 2021 free cash flow guidance includes a $300M payment of deferred payroll taxes. This excludes planned payments related to the restructuring of multi-employer pension plans.

Investor Webcast Details
The presentation will broadcast online at ir.kroger.com on March 31 from 9:00 a.m. (ET) to approximately 12:00 p.m. (ET). Click on Events & Presentations to access the event. An on-demand replay of the presentations will be available starting at approximately 5:00 p.m. (ET) on Thursday, April 1, 2021.

About The Kroger Co.
At The Kroger Co. (NYSE: KR), we are Fresh for Everyone™ and dedicated to our Purpose: To Feed the Human Spirit®. We are, across our family of companies, nearly half a million associates who serve 60 million households annually through a seamless shopping experience under a variety of banner names. We are committed to creating #ZeroHungerZeroWaste communities by 2025. To learn more about us, visit our newsroom and investor relations site.

Please refer to the supplemental information presented in the tables for reconciliations of the non-GAAP financial measures used in this press release to the most comparable GAAP financial measure and related disclosure.

This press release contains certain statements that constitute “forward-looking statements” about the future performance of the company. These statements are based on management’s assumptions and beliefs in light of the information currently available to it. Such statements are indicated by words or phrases such as “achieve,” “believe,” “contemplates,” “continue,” “deliver,” “expect,” “future,” “guidance,” “strategy,” “target,” “trends,” and “will.” Various uncertainties and other factors could cause actual results to differ materially from those contained in the forward-looking statements. These include the specific risk factors identified in “Risk Factors” in our annual report on Form 10-K for our last fiscal year and any subsequent filings, as well as the following:

• Kroger’s ability to achieve sales, earnings, incremental FIFO operating profit, and adjusted free cash flow goals may be affected by: COVID-19 related factors, risks and challenges, including among others, the length of time that the pandemic continues, the temporary inability of customers to shop due to illness, quarantine, or other travel restrictions or financial hardship, shifts in demand away from discretionary or higher priced products to lower priced products, or stockpiling or similar pantry-filling activities, reduced workforces which may be caused by, but not limited to, the temporary inability of the workforce to work due to illness, quarantine, or government mandates, temporary store closures due to reduced workforces or government mandates, or the availability and efficacy of a vaccine; labor negotiations or disputes; changes in the types and numbers of businesses that compete with Kroger; pricing and promotional activities of existing and new competitors, including non-traditional competitors, and the aggressiveness of that competition; Kroger’s response to these actions; the state of the economy, including interest rates, the inflationary and deflationary trends in certain commodities, changes in tariffs, and the unemployment rate; the effect that fuel costs have on consumer spending; volatility of fuel margins; changes in government-funded benefit programs and the extent and effectiveness of any COVID-19 stimulus packages; manufacturing commodity costs; diesel fuel costs related to Kroger’s logistics operations; trends in consumer spending; the extent to which Kroger’s customers exercise caution in their purchasing in response to economic conditions; the uncertainty of economic growth or recession; changes in inflation or deflation in product and operating costs; stock repurchases; Kroger’s ability to retain pharmacy sales from third party payors; consolidation in the healthcare industry, including pharmacy benefit managers; Kroger’s ability to negotiate modifications to multi-employer pension plans; natural disasters or adverse weather conditions; the effect of public health crises or other significant catastrophic events, including the coronavirus; the potential costs and risks associated with potential cyber-attacks or data security breaches; the success of Kroger’s future growth plans; the ability to execute our growth strategy and value creation model, including continued cost savings, growth of our alternative profit businesses, and widening and deepening our strategic moats of fresh, our brands, personalization, and seamless; and the successful integration of merged companies and new partnerships. Our ability to achieve these goals may also be affected by our ability to manage the factors identified above. Our ability to execute our financial strategy may be affected by our ability to generate cash flow.
• Kroger’s effective tax rate may differ from the expected rate due to changes in laws, the status of pending items with various taxing authorities, and the deductibility of certain expenses.

Kroger assumes no obligation to update the information contained herein. Please refer to Kroger’s reports and filings with the Securities and Exchange Commission for a further discussion of these risks and uncertainties.

View original content to download multimedia:http://www.prnewswire.com/news-releases/kroger-outlines-strategy-to-deliver-strong-and-sustainable-total-shareholder-return-by-leading-with-fresh-and-accelerating-with-digital-301259480.html

SOURCE The Kroger Co.